The present invention relates to the use of VEGF antagonists and a novel anti-&alpha；5&bgr；1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-&alpha；5&bgr；1 antibodies and methods of making and using them.
